Improving the flexibility of cell line development through utilization of platform approaches and suitable partnerships can reduce potential bottlenecks in the development pathway of novel biologics.
Simon Keen
Advertisement
Simon Keen, vice president Cell Line Development, Abzena
Articles by Simon Keen
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Zylidac Bio to Scale Prolific's Optogenetic Cell Line Platform to GMP
2
BioNTech, BMS to Pair Pumitamig With Trodelvy in Phase 3 First-Line TNBC Trial
3
Sanofi Begins Construction of EU-Backed Insulin Plant in Frankfurt
4
FDA Grants Accelerated Approval to Ultomiris as First C5 Inhibitor for IgA Nephropathy
5